The NeuClone Right from the Start® framework underpins our ability to deliver biosimilars with two critical properties: quality excellence and price competitiveness.
Producing biosimilars of the highest quality at an affordable price is critical to clinical and commercial success in both developed and rest-of-world (RoW) markets. Our Right from the Start® processes and technologies ensure these outcomes through four key elements:
The NeuClone Right from the Start® framework underpins our ability to deliver biosimilars with two critical properties: quality excellence and price competitiveness.
Producing biosimilars of the highest quality at an affordable price is critical to clinical and commercial success in both developed and rest-of-world (RoW) markets. Our Right from the Start® processes and technologies ensure these outcomes through three key elements:
Early focus on the primary structure (amino acid sequence) of originator products through proprietary processes – including peptide mass fingerprinting, intact mass and X-ray crystallography – ensures the right sequence, from the beginning of development.
NeuClone’s Biosimilarity by Design™ approach is based on QbD principles, to test and confirm biosimilarity from the start. We also use world-leading internal and independent external analytics capabilities for every stage of biosimilar development.
In-house development and testing of cell-based assays confirm biosimilar function in the native cellular environment.
NeuClone rapidly and cost effectively develops biosimilars through its proprietary NeuMAX® technology.
